放射性核素反义治疗

欧晓红

放射性核素反义治疗

欧晓红

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 6: (246-248)

引用本文:

Citation:

放射性核素反义治疗

欧晓红

610041 成都, 四川大学华西医院核医学科

作者简介: 欧晓红(1974-),女,四川广安人,博士研究生,主要从事放射性反义治疗研究。;

中图分类号: R817.5;Q74

Radionuclide antisense therapy

OU Xiao-hong

Department of Nuclear Medicine, West China Hospital of Si Chuan University, Chengdu 610041, China
CLC number: R817.5;Q74

摘要: 放射性核素反义治疗将反义寡核苷酸阻断癌基因表达作用及放射性核素杀伤癌细胞作用结合在一起,是一项新兴的治疗技术。这项研究目前仍处于初步阶段,只有少量放射性寡核苷酸细胞毒性、动物体内药代动力学及组织学分布的报道。简要综述了目标基因的选择和反义寡核苷酸的标记、导入细胞及其毒副作用等几个放射性核素反义治疗有关的重要环节及其最新进展。
- 放射性核素 /
- 反义治疗 /
- 寡核苷酸
Abstract: Radionuclide antisense therapy achieves the joint goals of antisense therapy and internal radioation therapy.There have been a small number of investigations on the radionuclide antisense therapy in tissue culture and in animal studies.Considerable research is required before this novel technique can become a working practice.We reviewed some question and development on the radionuclide antisense therapy,such as selection of the target gene sequence,labelling the antisense oligonucleotide,improvement of the uptake and target of radionuclide antisense oligonucleotides and evaluation of the toxicity of the radionuclide antisense therapy.
- radionuclide /
- antisense therapy /
- oligonucleotide
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Casey BP, Glazer PM. Gene targeting via triple-helix formation[J]. Prog Nucleic Acid Res Mol Biol, 2001, 67(2):163-192.
[2]	Temsamani J, Agrawal S. Antisense oligonucleotides as antiviral agents[J]. Adv Antiviral Drug Des, 1996, 10(1):21-39.
[3]	Panyutin IG, Neumann RD. Sequence specific DNA breaks producd by triplex-directed decay of iodine-125[J]. Acta Oncol, 2000, 35(7):817-823.
[4]	Cammilleri S, Perdereau B, Brixy F, et al. Imaging and biodistribution of ¹²⁵I tyramine oligonucleotide in nude mice bearing human breast tumor. Preliminary report[J]. Bull Cancer Paris, 1996, 83(1):23-26.
[5]	Sedelnikova OA, Panyutin IG, Thierry AR, et al. Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells[J]. J Nucl Med, 1998, 39(8):1412-1418.
[6]	Karamychev VN, Panyutin IG, Kim MK, et al. DNA cleavage by ¹¹¹In-labeled oligodeoxyribonucleotides[J]. J Nucl Med, 2000, 41(6):1093-1101.
[7]	Winnard PJ, Chang F, Rusckowski M, et al. Preparation and use of NHS MAG₃ for technetium-99m labeling of DNA[J]. Nucl Med Biol, 1997, 24(5):425-432.
[8]	Fujibayashi Y, Nakagawa K, Waki A, et al. Basic studies on the ¹¹¹In labeled antisense oligonucleutide for tumor imaging[J]. Kaku Igaku, 1996, 33(2):115-122.
[9]	Watanabe N, Sawai H, Endo K, et al. Labeling of phosphorothioate antisense oligonucleotides with yttrium-90[J]. Nucl Med Biol, 1999, 26(2):239-243.
[10]	Fujibayashi Y, Yoshimi E, Waki A, et al. A novel ¹¹¹In-la-beled antisense DNA probe with multi-chelating sites (MCSprobe) showing high specific radioactivity and labeling efficiency[J]. Nucl Med Biol, 1999, 26(1):17-21.
[11]	Gonzalez Ferreiro M, Tillman L, Hardee G. Characterization of complexes of an antisense oligonucleotide with protamine and poly-L-lysine salts[J]. J Control Release, 2001, 73(2-3):381-390.
[12]	Sugano M, Makino N, Sawada S, et al. Effect of antisense oligodeoxynucleotides against cholestryl estertansfer protein on the development of atherosclerosis in cholesterol-fed rabbits[J]. J Biol Chem, 1998, 273(9):5033-5036.
[13]	Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers[J]. Crit Rev Ther Carrier Syst, 1998, 15(6):587-627.
[14]	Agrawal S. Antisense oligonucleotides:towards clinical trials[J]. Tibtech, 1996, 14(10):376-387.
[15]	Hnatowich DJ, Winnard PJ, Virzi F, et al. Labeling deoxyribonucleic acid oligonucleotides with ⁹⁹Tc^m[J]. J Nucl Med, 1995, 36(12):2306-2314.
[16]	Kairemo KJ, Tenhunen M, Jekunen AP. Dosimetry of radionuclide therapy using radiophosphonated autisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data[J]. Antisense Nucleic Acid Drug Dev, 1996, 6(3):215-220.

[1]	陈建伟 . 放射性核素近距离治疗血管再狭窄的现状和进展. 国际放射医学核医学杂志, 2002, 26(3): 97-100.
[2]	刘彧 . 放射性核素在关节炎治疗中的应用. 国际放射医学核医学杂志, 2003, 27(2): 59-62.
[3]	秦光明 . 肿瘤核素反义显像技术的研究现状与展望. 国际放射医学核医学杂志, 2001, 25(5): 213-216.
[4]	苏新辉 , 王荣福 , 刘秀杰 . 核素内照射治疗在血管成型术后预防再狭窄的研究进展. 国际放射医学核医学杂志, 1999, 23(4): 164-166.
[5]	陈立波 , 朱瑞森 . NIS在肿瘤核素基因显像与治疗中的应用研究. 国际放射医学核医学杂志, 2005, 29(2): 70-73.
[6]	任均田 , 林学颜 . 放射免疫显像与治疗的应用进展. 国际放射医学核医学杂志, 1995, 19(2): 57-59.
[7]	张春 . 受体介导的反义治疗研究. 国际放射医学核医学杂志, 2000, 24(3): 104-106.
[8]	杨卫东 , 朱承谟 . 肿瘤反义显像技术中的若干问题. 国际放射医学核医学杂志, 1998, 22(6): 244-247.
[9]	郑玉明 . 敷贴治疗寻常型银屑病的疗效分析. 国际放射医学核医学杂志, 2015, 39(4): 300-302. doi: 10.3760/cma.j.issn.1673-4114.2015.04.006
[10]	王任飞 , 谭建 . 血管腔内近距离照射预防介入治疗后再狭窄的研究现状. 国际放射医学核医学杂志, 2001, 25(4): 153-157.

点击查看大图

计量

文章访问数: 1138
HTML全文浏览量: 130
PDF下载量: 2

放射性核素反义治疗

欧晓红

作者简介:欧晓红(1974-),女,四川广安人,博士研究生,主要从事放射性反义治疗研究。

610041 成都, 四川大学华西医院核医学科

收稿日期: 2001-11-20

关键词:

摘要: 放射性核素反义治疗将反义寡核苷酸阻断癌基因表达作用及放射性核素杀伤癌细胞作用结合在一起,是一项新兴的治疗技术。这项研究目前仍处于初步阶段,只有少量放射性寡核苷酸细胞毒性、动物体内药代动力学及组织学分布的报道。简要综述了目标基因的选择和反义寡核苷酸的标记、导入细胞及其毒副作用等几个放射性核素反义治疗有关的重要环节及其最新进展。